Molly Hiatt, MD
Hospitalist · Omaha, NENPI 1760902977
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.3% of the total. Reporting peaked in 2021 at $366 and has fallen 76.0% since, to $88 in 2022.
Across 35 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$162
- Pfizer$139
- Johnson & Johnson$139
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$50
- Boston Scientific$46
- Janssen Scientific Affairs, LLC$17
- plus $43 from 3 others
What the payments were for
- Food & beverage$595100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 10 | $162 |
| Pfizer | 8 | $139 |
| Johnson & Johnson | 8 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Boston Scientific | 2 | $46 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$595 in reported general payments places this provider in the 80th percentile of 124 hospitalist providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 27 | $375 |
| Gabapentin | 20 | $294 |
| Carvedilol | 22 | $279 |
| Fenofibrate | 11 | $259 |
| Tamsulosin Hcl | 15 | $243 |
| Quetiapine Fumarate | 11 | $200 |
| Atorvastatin Calcium | 22 | $124 |
| ClopidogrelClopidogrel Bisulfate | 17 | $107 |
| Metoprolol Succinate | 14 | $103 |
| Furosemide | 11 | $39 |
| Prednisone | 12 | $11 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Omaha
- Bryce SchutteOmaha$2K
- Anthony MacdissiOmaha$2K
- Stephen TothOmaha$2K
- Joseph ThirumalareddyOmaha$2K
- Sunil NairOmaha$1K
- Adam MacdissiOmaha$1K
- Akshat SoodOmaha$1K
- Pooja DeshmukhOmaha$1K
- Jill PuetzOmaha$975
- Durgalakshmi DuraikannanOmaha$907
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.